EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Oral and inhaled corticosteroid dose reductions with tezepelumab versus placebo in patients with severe, uncontrolled asthma from DESTINATION

Michael E Wechsler, Daiana Stolz, Njira L Lugogo, Scott Caveney, Gun Almqvist, Artur Bednarczyk, Ales Kotalik, Shradha Chandarana, Christopher S Ambrose

The Journal of Allergy and Clinical Immunology: In Practice · 2024-11 · 12 (11) · 3128-3131.e2

DOI: 10.1016/j.jaip.2024.08.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2024-11. Verfasst von Michael E Wechsler und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, Colo. Electronic address: mikewechsler@gmail.com. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amgen, AstraZeneca PLC.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with severe asthma require high-dosage inhaled corticosteroids (ICS) and other controller medications for disease control, and may additionally require oral corticosteroids (OCS), which are associated with considerable adverse effects.1,2 Once asthma control is established, the Global Initiative for Asthma recommends gradually stepping down treatments to find the patient’s lowest ICS and OCS doses that control both symptoms and exacerbations.3

Autor:innen und Institutionen

  • Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, Colo. Electronic address: mikewechsler@gmail.com.
  • University Medical Center Freiburg, Clinic of Pneumology, Department of Medicine, University of Freiburg, Freiburg, Germany.
  • Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Mich.
  • Global Development, Inflammation, R&D, Amgen, Thousand Oaks, Calif.
  • Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Warsaw, Poland.

Förderung

  • Amgen
  • AstraZeneca PLC

Zitieren

APA

Wechsler, M. E., Stolz, D., Lugogo, N. L., Caveney, S., Almqvist, G., Bednarczyk, A., Kotalik, A., Chandarana, S., & Ambrose, C. S. (2024). Oral and inhaled corticosteroid dose reductions with tezepelumab versus placebo in patients with severe, uncontrolled asthma from DESTINATION. The Journal of Allergy and Clinical Immunology: In Practice, 12(11), 3128-3131.e2. https://doi.org/10.1016/j.jaip.2024.08.008

Vancouver

Wechsler ME, Stolz D, Lugogo NL, Caveney S, Almqvist G, Bednarczyk A, et al. Oral and inhaled corticosteroid dose reductions with tezepelumab versus placebo in patients with severe, uncontrolled asthma from DESTINATION. The Journal of Allergy and Clinical Immunology: In Practice. 2024;12(11):3128-3131.e2. doi:10.1016/j.jaip.2024.08.008

BibTeX
@article{Wechsler2024,
  author = {Wechsler, Michael E and Stolz, Daiana and Lugogo, Njira L and Caveney, Scott and Almqvist, Gun and Bednarczyk, Artur and Kotalik, Ales and Chandarana, Shradha and Ambrose, Christopher S},
  title = {Oral and inhaled corticosteroid dose reductions with tezepelumab versus placebo in patients with severe, uncontrolled asthma from DESTINATION},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2024},
  volume = {12},
  number = {11},
  pages = {3128--3131.e2},
  doi = {10.1016/j.jaip.2024.08.008}
}
Kostenlos starten →